Dual human epidermal growth factor receptor 2 blockade: Another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 612-622

  Zardavas, Dimitrios ^a   Bozovic Spasojevic, Ivana ^a   De Azambuja, Evandro ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

breast cancer; dual antihuman epidermal growth factor receptor 2 blockade; human epidermal growth factor receptor 2

Indexed keywords

AFATINIB; AROMATASE INHIBITOR; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIRUBICIN; FLUOROURACIL; LAPATINIB; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

ABDOMINAL PAIN; ALOPECIA; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DERMATITIS; DIARRHEA; DRUG HYPERSENSITIVITY; DRY SKIN; DYSPNEA; FATIGUE; GRANULOCYTOPENIA; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INFLAMMATION; LEUKOPENIA; LIVER TOXICITY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; QUINAZOLINES; QUINOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84868205001     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328358a29a     Document Type: Review

References (40)

1. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55:685-696.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
3. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51.
4. Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011; 9:16-32.
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
6. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-475.
7. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379:633-640.
8. Chang J, Mayer I, Forero-Torres A, et al. TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. 2011 ASCO Annual Meeting, Oral Abstract Session, Breast Cancer-HER2/ER, Abstract No 505. J Clin Oncol 2011; (suppl; abstr 505).
9. Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB Study. J Clin Oncol [Internet] 2012; http://www. ncbi.nlm.nih.gov/pubmed/ 22493419. [Accessed 17 May 2012]
10. Holmes F, Nagarwala Y, Espina V, et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. 2011 ASCO Annual Meeting, Oral Abstract Session, Breast Cancer-HER2/ER, Abstract No 506. J Clin Oncol 2011; (suppl; abstr 506).
11. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:25-32.
12. Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA) [abstract S5-6]. San Antonio Breast Cancer Symposium. San Antonio, Texas; 2010.
13. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124-1130.
14. Swaby R, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. 2009 ASCO Annual Meeting, Oral Abstract Session, Breast Cancer-Metastatic, Abstract No 1004. J Clin Oncol 2009; (suppl; abstr 1004).
15. Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008; 14:2710-2716.
16. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-1144.
17. Baselga J, Corté s J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-119.
18. Higgins M, Gabrail N, Miller K, et al. A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer. 2011 ASCO Annual Meeting, Trials in Progress Poster Session, Abstract No TPS119. J Clin Oncol 2011; (suppl; abstr TPS119).
19. Miller K, Gianni L, Fabrice A, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). 2010 ASCO Annual Meeting, Poster Discussion Session, Breast Cancer-Metastatic, Abstract No 1012. J Clin Oncol 2010; (suppl; abstr 1012).
20. Dieras VHN, Albain K, Burris H, et al. A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Cancer Res 2010; 70:1.
21. Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24:6213-6221.
22. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28:803-814.
23. Tomasello G, de Azambuja E, Dinh P, et al. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008; 8:1883-1890.
24. Bozovic I,Capelan M,DeAzambuja E. Accrual target reached and changes after IDMC recommendation. BIG (Breast International Group) Newsletter. 2011;
25. http://www.breastinternationalgroup.org/Portals/BIG//Eloket/7077/BIG% 20NL%20Vol.%2013.2%20December%202011.pdf. [Accessed 11 June 2012].
26. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28:1301-1307.
27. Canonici A, Pedersen K, Walsh N, et al. Effect of neratinib (N) alone and in combination with trastuzumab (T) in HER2-positive breast cancer (BC) cell lines. 2012 ASCO Annual Meeting, General Poster Session, Breast Cancer-HER2/ER, Abstract No 632. J Clin Oncol 2012; (suppl; abstr 632).
28. Jankowitz R, Abraham J, Tan AR, et al. A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSAB FB-8. J Clin Oncol 2012; (suppl; abstr 611).
29. Hickish T, Wheatley D, Lin N, et al. Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with Trastuzumab. Cancer Res 2010; 69 (24 Suppl):5060-15060.
30. Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast cancer research and treatment [Internet]. (2012). http://www.ncbi.nlm.nih.gov/pubmed/ ref22418700. [Accessed 17 May 2012]
31. Hughes JB, Berger C, Rødland MS, et al. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009; 8:1885-1892.
32. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-9336.
33. Lenihan D, Suter T, Brammer M, et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012; 23:791-800.
34. Von Minckwitz GBJ, Bradbury I, De Azambuja E, et al. Adjuvant Pertuzumab and HerceptIN iniTial TherapY of breast cancer: APHINITY (BIG 4-11/BO25126/TOC439g). Cancer Res 2011; 71:602.
35. McDonagh CF, Huhalov A, Harms BD, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-593.
36. Richards D, Braiteh F, Anthony S, et al. A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors. 2012 ASCO Annual Meeting, General Poster Session, Developmental Therapeutics-Experimental Therapeutics, Abstract No TPS3111. J Clin Oncol 2012; (suppl; abstr TPS3111).
37. LoRusso PM, Weiss D, Guardino E, et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011; 17:6437-6447.
38. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698-2704.
39. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398-405.
40. Modi S, Elias A, LoRusso PM, et al. Results froma phase Ib study of trastuzumab emtasine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. 2012 ASCO Annual Meeting, Poster Discussion Session, Breast Cancer-HER2/ER, Abstract No 528. J Clin Oncol 2012; (suppl; abstr 528).